海南医学
海南醫學
해남의학
HAINAN MEDICAL JOURNAL
2015年
2期
172-174
,共3页
动脉硬化闭塞症%盐酸沙格雷酯%腔内治疗术%疗效%安全性
動脈硬化閉塞癥%鹽痠沙格雷酯%腔內治療術%療效%安全性
동맥경화폐새증%염산사격뢰지%강내치료술%료효%안전성
Infrapopliteal arteriosclerotic occlusive disease%Hydrochloric sarpogrelate%Transluminal angio-plasty%Efficacy%Safety
目的:探讨动脉硬化闭塞症膝下动脉腔内治疗术后应用盐酸沙格雷酯后续治疗的疗效及安全性。方法选择我院2010年4月至2013年1月收治的100例采用膝下动脉腔内治疗成功的动脉硬化闭塞症患者作为研究对象,按术后治疗方案分为实验组和对照组各50例,对照组采用阿司匹林联合硫酸氢氯吡格雷治疗,实验组患者在此基础上加用盐酸沙格雷酯治疗,比较两组患者术前、术后1个月、3个月和6个月的踝肱指数(ABI)、血管通畅率以及截肢、静息痛和间歇性跛行情况。结果实验组患者在术后6个月时间歇性跛行发生率远低于对照组,差异有统计学意义(P<0.05),但两组患者在其他时段的截肢、静息痛、间歇性跛行发生率比较差异均无统计学意义(P>0.05)。手术后两组患者ABI指数较术前均有较大改善,术后1个月、3个月和6个月与术前比较差异均有统计学意义(P<0.05),但两组患者在各时段的ABI指数和血管通畅率比较差异均无统计学意义(P>0.05)。结论盐酸沙格雷酯可在一定程度上降低动脉硬化闭塞症膝下动脉腔内治疗术后间歇性跛行的发生风险,安全性良好,对改善预后有着积极的促进作用。
目的:探討動脈硬化閉塞癥膝下動脈腔內治療術後應用鹽痠沙格雷酯後續治療的療效及安全性。方法選擇我院2010年4月至2013年1月收治的100例採用膝下動脈腔內治療成功的動脈硬化閉塞癥患者作為研究對象,按術後治療方案分為實驗組和對照組各50例,對照組採用阿司匹林聯閤硫痠氫氯吡格雷治療,實驗組患者在此基礎上加用鹽痠沙格雷酯治療,比較兩組患者術前、術後1箇月、3箇月和6箇月的踝肱指數(ABI)、血管通暢率以及截肢、靜息痛和間歇性跛行情況。結果實驗組患者在術後6箇月時間歇性跛行髮生率遠低于對照組,差異有統計學意義(P<0.05),但兩組患者在其他時段的截肢、靜息痛、間歇性跛行髮生率比較差異均無統計學意義(P>0.05)。手術後兩組患者ABI指數較術前均有較大改善,術後1箇月、3箇月和6箇月與術前比較差異均有統計學意義(P<0.05),但兩組患者在各時段的ABI指數和血管通暢率比較差異均無統計學意義(P>0.05)。結論鹽痠沙格雷酯可在一定程度上降低動脈硬化閉塞癥膝下動脈腔內治療術後間歇性跛行的髮生風險,安全性良好,對改善預後有著積極的促進作用。
목적:탐토동맥경화폐새증슬하동맥강내치료술후응용염산사격뢰지후속치료적료효급안전성。방법선택아원2010년4월지2013년1월수치적100례채용슬하동맥강내치료성공적동맥경화폐새증환자작위연구대상,안술후치료방안분위실험조화대조조각50례,대조조채용아사필림연합류산경록필격뢰치료,실험조환자재차기출상가용염산사격뢰지치료,비교량조환자술전、술후1개월、3개월화6개월적과굉지수(ABI)、혈관통창솔이급절지、정식통화간헐성파행정황。결과실험조환자재술후6개월시간헐성파행발생솔원저우대조조,차이유통계학의의(P<0.05),단량조환자재기타시단적절지、정식통、간헐성파행발생솔비교차이균무통계학의의(P>0.05)。수술후량조환자ABI지수교술전균유교대개선,술후1개월、3개월화6개월여술전비교차이균유통계학의의(P<0.05),단량조환자재각시단적ABI지수화혈관통창솔비교차이균무통계학의의(P>0.05)。결론염산사격뢰지가재일정정도상강저동맥경화폐새증슬하동맥강내치료술후간헐성파행적발생풍험,안전성량호,대개선예후유착적겁적촉진작용。
Objective To evaluate the efficacy and safety of hydrochloric sarpogrelate in follow-up treat-ment of percutaneous transluminal angioplasty in infrapopliteal arteriosclerotic occlusive disease. Methods One hun-dred patients from April 2010 to February 2013 in our hospital were chosen as the study subjects, which were divided into experimental group and control group. The control group (n=50) was treated with aspirin and clopidogrel bisul-fate, and the experimental group (n=50) was treated with hydrochloric sarpogrelate on the basis of control group. The ankle brachial index (ABI), vascular patency and amputation, rest pain and intermittent claudication were compared before surgery, one month, three months, and six months after surgery. Results The incidence of intermittent claudica-tion in the experimental group was significantly lower than that in the control group six months after surgery (P<0.05), but there was no statistically significant difference between the two groups in rest pain, incidence of intermittent claudi-cation at other time points (P>0.05). ABI index was significantly improved in the two groups 1 month, 3 months, 6 months after surgery, compared with that before surgery (P<0.05). There was no statistically significant difference be-tween the two groups at the same time points in ABI index and vascular patency rate (P>0.05). Conclusion Hydro-chloric sarpogrelate could reduce the risk of intermittent claudication on patents with percutaneous transluminal angio-plasty in infrapopliteal arteriosclerotic occlusive disease, with good safety.